A detailed history of Group One Trading, L.P. transactions in Hookipa Pharma Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 59,004 shares of HOOK stock, worth $223,625. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,004
Previous 17,404 239.03%
Holding current value
$223,625
Previous $12,000 183.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.59 - $1.04 $24,544 - $43,264
41,600 Added 239.03%
59,004 $34,000
Q4 2023

Feb 14, 2024

SELL
$0.42 - $0.86 $14,565 - $29,824
-34,680 Reduced 66.58%
17,404 $14,000
Q3 2023

Nov 09, 2023

SELL
$0.58 - $0.91 $8,404 - $13,186
-14,491 Reduced 21.77%
52,084 $32,000
Q2 2023

Aug 09, 2023

BUY
$0.71 - $1.97 $18,371 - $50,973
25,875 Added 63.57%
66,575 $58,000
Q1 2023

May 12, 2023

SELL
$0.72 - $1.03 $3,399 - $4,863
-4,722 Reduced 10.4%
40,700 $30,000
Q4 2022

Feb 09, 2023

BUY
$0.73 - $14.6 $9,993 - $199,874
13,690 Added 43.14%
45,422 $36,000
Q3 2022

Nov 09, 2022

SELL
$1.27 - $15.0 $57,745 - $682,035
-45,469 Reduced 58.9%
31,732 $43,000
Q2 2022

Aug 11, 2022

BUY
$1.33 - $2.31 $38,566 - $66,983
28,997 Added 60.15%
77,201 $126,000
Q1 2022

May 12, 2022

BUY
$1.26 - $2.52 $55,776 - $111,552
44,267 Added 1124.38%
48,204 $110,000
Q4 2021

Feb 11, 2022

BUY
$2.33 - $5.94 $8,010 - $20,421
3,438 Added 688.98%
3,937 $9,000
Q3 2021

Nov 12, 2021

SELL
$5.89 - $9.35 $10,013 - $15,895
-1,700 Reduced 77.31%
499 $3,000
Q2 2021

Aug 10, 2021

BUY
$9.16 - $19.51 $20,142 - $42,902
2,199 New
2,199 $20,000

Others Institutions Holding HOOK

About HOOKIPA Pharma Inc.


  • Ticker HOOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,654,500
  • Market Cap $196M
  • Description
  • HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...
More about HOOK
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.